Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Veerman

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Clinical Genetics|June 26, 2002
Early development of megarectum in myotonic dystrophyB Meijers, M Miserez, G Veerman-Wouters, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracilC L van der Wilt, K Smid, G Veerman, et al.
Biochemical Pharmacology|August 17, 1993
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell linesV W Ruiz van Haperen, G Veerman, J B Vermorken, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine)V W Ruiz van Haperen, G Veerman, C J van Moorsel, et al.
Oncology Reports|May 20, 2011
In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of four diorganotin compoundsM Gielen, R Willem, A Bouhdid, et al.
Biochemical Pharmacology|April 12, 1996
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidineV W van Haperen, G Veerman, J B Vermorken, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell linesA M Bergman, H M Pinedo, G Veerman, et al.
Advances in Experimental Medicine and Biology|January 1, 1991
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine)V W Ruiz van Haperen, G Veerman, P Noordhuis, et al.
Seminars in Oncology|August 1, 1995
Schedule-dependent antitumor effect of gemcitabine in in vivo model systemB J Braakhuis, V W Ruiz van Haperen, E Boven, et al.
Seminars in Oncology|August 1, 1995
Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780V W Ruiz van Haperen, G Veerman, S Eriksson, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Clinical Genetics|June 26, 2002
Early development of megarectum in myotonic dystrophyB Meijers, M Miserez, G Veerman-Wouters, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
The role of thymidine kinase activity in murine colon tumours treated with 5-fluorouracilC L van der Wilt, K Smid, G Veerman, et al.
Biochemical Pharmacology|August 17, 1993
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell linesV W Ruiz van Haperen, G Veerman, J B Vermorken, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine)V W Ruiz van Haperen, G Veerman, C J van Moorsel, et al.
Oncology Reports|May 20, 2011
In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of four diorganotin compoundsM Gielen, R Willem, A Bouhdid, et al.
Biochemical Pharmacology|April 12, 1996
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidineV W van Haperen, G Veerman, J B Vermorken, et al.
Advances in Experimental Medicine and Biology|May 23, 1998
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell linesA M Bergman, H M Pinedo, G Veerman, et al.
Advances in Experimental Medicine and Biology|January 1, 1991
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine)V W Ruiz van Haperen, G Veerman, P Noordhuis, et al.
Seminars in Oncology|August 1, 1995
Schedule-dependent antitumor effect of gemcitabine in in vivo model systemB J Braakhuis, V W Ruiz van Haperen, E Boven, et al.
Seminars in Oncology|August 1, 1995
Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780V W Ruiz van Haperen, G Veerman, S Eriksson, et al.
Pageof 4